Literature DB >> 9602814

Long-term prognosis after healed amputation in patients with diabetes.

J Larsson1, C D Agardh, J Apelqvist, A Stenström.   

Abstract

In this prospective study, mortality, rehabilitation, and new amputations on the same or on the contralateral leg were studied in 189 patients with diabetes who had achieved healing of an index amputation. Ninety-three patients had achieved healing after an index minor (below the ankle) and 96 after an index major (above the ankle) amputation, precipitated by a foot ulcer. The healing time was 29 weeks (range, 3-191 weeks) with a minor amputation and 8 weeks (range, 3-104 weeks) with a primary major amputation. The mortality 1, 3, and 5 years after the index amputation was 15%, 38%, and 68%, respectively, and was higher in patients who had achieved healing after major amputation than in patients achieving healing after minor amputation. The rate of new amputations after 1, 3, and 5 years of observation was 14%, 30%, and 49%, respectively. There was no difference among patients with an index minor and those with an index major amputation. The rate of new major amputations was 9%, 13%, and 23%, respectively, and was higher in patients with an index major amputation. Eighty-five percent of new amputations were precipitated by a foot ulcer. Patients living independently before the index amputation returned to living independently more often after a minor than a major amputation (93% versus 61%). One year after the index amputation, 70% of patients who had achieved healing after having a minor amputation and who could walk 1 km or more before amputation had regained this walking capacity, compared with 19% of patients having a major amputation. Seventy percent of patients with an index transtibial amputation who could walk before amputation were fitted with a prosthesis, and 52% were using it regularly. Patients with diabetes who had an index major amputation had a higher mortality, an equal rate of new amputation, and a lower rehabilitation potential than did patients who had an index minor amputation.

Entities:  

Mesh:

Year:  1998        PMID: 9602814

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  43 in total

Review 1.  Risk factors for diabetic neuropathy and foot ulceration.

Authors:  A Adler
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 2.  Diabetic foot infections: stepwise medical and surgical management.

Authors:  David G Armstrong; Benjamin A Lipsky
Journal:  Int Wound J       Date:  2004-06       Impact factor: 3.315

Review 3.  [Minor amputations - a maxi task. Part 1: From the principles to transmetatarsal amputation].

Authors:  R Matamoros; G Riepe; P Drees
Journal:  Chirurg       Date:  2012-10       Impact factor: 0.955

Review 4.  Epidemiology of diabetes and diabetes-related complications.

Authors:  Anjali D Deshpande; Marcie Harris-Hayes; Mario Schootman
Journal:  Phys Ther       Date:  2008-09-18

Review 5.  Diagnostics and treatment of the diabetic foot.

Authors:  Jan Apelqvist
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

Review 6.  Therapeutic strategies for enhancing angiogenesis in wound healing.

Authors:  Austin P Veith; Kayla Henderson; Adrianne Spencer; Andrew D Sligar; Aaron B Baker
Journal:  Adv Drug Deliv Rev       Date:  2018-09-26       Impact factor: 15.470

7.  Heel ulcers do heal in patients with diabetes.

Authors:  Hedvig Örneholm; Jan Apelqvist; Jan Larsson; Magnus Eneroth
Journal:  Int Wound J       Date:  2016-08-04       Impact factor: 3.315

8.  [Diabetic foot syndrome from the perspective of angiology and diabetology].

Authors:  H Lawall; C Diehm
Journal:  Orthopade       Date:  2009-12       Impact factor: 1.087

Review 9.  [Diabetic foot syndrome].

Authors:  H Lawall; H Reike
Journal:  Internist (Berl)       Date:  2009-08       Impact factor: 0.743

10.  [Epidemiology and classification of diabetic foot syndrome].

Authors:  J Teichmann; D Sabo
Journal:  Orthopade       Date:  2009-12       Impact factor: 1.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.